Extractables and leachables (E&L) represent an important class of impurities in pharmaceutical products that can arise from interactions between drug formulations and packaging materials, manufacturing components, or delivery devices, and migrate into drug products during manufacturing, storage, or administration.
Biocatalysis is a central pillar of modern organic synthesis, enabling researchers to synthesize molecules in mild, environmentally friendly conditions with high selectivity and exceptional efficiency.
Cyclic peptides offer unique biochemical and therapeutic benefits, making them an attractive alternative to small molecules and antibodies in some instances. This white paper outlines the strategic advantages of cyclic peptides and the capabilities required to manufacture them reliably at scale.
The pharmaceutical industry faces increasing pressure to deliver innovative therapies rapidly while embracing sustainable, environmentally responsible practices that ensure efficiency and safety throughout the drug development process. This white paper demonstrates how integrating green chemistry principles at the discovery stage delivers both scientific and strategic advantages for organizations aiming to improve efficiency and sustainability.
-1-1.png)
Seeking to mitigate increasing supply chain risks, pharmaceutical companies have identified “China Plus One” as a strategic imperative. Under this risk-management model, companies diversify their supply chains to include at least one other country in addition to China, allowing them to continue benefitting from China';s manufacturing footprint while avoiding the risks associated with relying solely on one country.
-3.png)
-2-1.png)
-2.png)
.png)
